Cited 1 times in
Prolonged dual antiplatelet therapy after drug-eluting stent implantation in patients with diabetes mellitus: A nationwide retrospective cohort study
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 김중선 | - |
dc.contributor.author | 남정모 | - |
dc.contributor.author | 이승준 | - |
dc.contributor.author | 최동훈 | - |
dc.contributor.author | 홍성진 | - |
dc.contributor.author | 홍명기 | - |
dc.contributor.author | 고영국 | - |
dc.contributor.author | 김병극 | - |
dc.contributor.author | 장양수 | - |
dc.contributor.author | 박은철 | - |
dc.contributor.author | 안철민 | - |
dc.contributor.author | 이승준 | - |
dc.contributor.author | 최동우 | - |
dc.date.accessioned | 2022-12-22T03:09:22Z | - |
dc.date.available | 2022-12-22T03:09:22Z | - |
dc.date.issued | 2022-08 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/191809 | - |
dc.description.abstract | Background: Optimal duration of dual antiplatelet therapy (DAPT) in patients with diabetes mellitus (DM) who have undergone drug-eluting stent (DES) implantation is not clearly established. This study sought to impact of DAPT duration on real-world clinical outcome in patients with or without DM. Methods: Using a nationwide cohort database, we investigate the association between DAPT duration and clinical outcome between 1 and 3 years after percutaneous coronary intervention (PCI). Primary outcome was all-cause death. Secondary outcomes were cardiovascular death, myocardial infarction, and composite bleeding events. After weighting, 90,100 DES-treated patients were included; 29,544 patients with DM and 60,556 without DM; 31,233 patients with standard DAPT (6-12 months) and 58,867 with prolonged DAPT (12-24 months). Results: The incidence of all-cause death was significantly lower in patients with prolonged DAPT [8.3% vs. 10.5% in those with standard DAPT, hazard ratio (HR) 0.78, 95% confidence interval (CI) 0.72-0.84] in diabetic patients and non-diabetic patients (4.5% vs. 5.0% in those with standard DAPT, HR 0.89, 95% CI 0.83-0.96). The incidence of composite bleeding events was 5.7% vs. 5.4%, respectively, (HR 1.07, 95% CI 0.96-1.18) in diabetic patients and 5.6% vs. 5.0%, respectively, in non-diabetic patients (HR 1.13, 95% CI 1.05-1.21). There was a significant interaction between the presence of DM and DAPT duration for all-cause death (p for interaction, pint = 0.01) that further favored prolonged DAPT in diabetic patients. However, there was no significant interaction between the presence of DM and DAPT duration for composite bleeding events (pint = 0.38). Conclusions: This study showed that prolonged rather than standard DAPT might be clinically beneficial in diabetic patients with DES implantation. Trial registration: ClinicalTrial.gov (NCT04715594). | - |
dc.description.statementOfResponsibility | open | - |
dc.format | application/pdf | - |
dc.language | English | - |
dc.publisher | Frontiers Media S.A. | - |
dc.relation.isPartOf | FRONTIERS IN CARDIOVASCULAR MEDICINE | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.title | Prolonged dual antiplatelet therapy after drug-eluting stent implantation in patients with diabetes mellitus: A nationwide retrospective cohort study | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Internal Medicine (내과학교실) | - |
dc.contributor.googleauthor | Seung-Jun Lee | - |
dc.contributor.googleauthor | Dong-Woo Choi | - |
dc.contributor.googleauthor | Choongki Kim | - |
dc.contributor.googleauthor | Yongsung Suh | - |
dc.contributor.googleauthor | Sung-Jin Hong | - |
dc.contributor.googleauthor | Chul-Min Ahn | - |
dc.contributor.googleauthor | Jung-Sun Kim | - |
dc.contributor.googleauthor | Byeong-Keuk Kim | - |
dc.contributor.googleauthor | Young-Guk Ko | - |
dc.contributor.googleauthor | Donghoon Choi | - |
dc.contributor.googleauthor | Eun-Cheol Park | - |
dc.contributor.googleauthor | Yangsoo Jang | - |
dc.contributor.googleauthor | Chung-Mo Nam | - |
dc.contributor.googleauthor | Myeong-Ki Hong | - |
dc.identifier.doi | 10.3389/fcvm.2022.954704 | - |
dc.contributor.localId | A00961 | - |
dc.contributor.localId | A01264 | - |
dc.contributor.localId | A02927 | - |
dc.contributor.localId | A04053 | - |
dc.contributor.localId | A05648 | - |
dc.contributor.localId | A04403 | - |
dc.contributor.localId | A04391 | - |
dc.contributor.localId | A00127 | - |
dc.contributor.localId | A00493 | - |
dc.contributor.localId | A03448 | - |
dc.contributor.localId | A01618 | - |
dc.relation.journalcode | J04002 | - |
dc.identifier.eissn | 2297-055X | - |
dc.identifier.pmid | 36035946 | - |
dc.subject.keyword | coronary artery disease | - |
dc.subject.keyword | diabetes mellitus | - |
dc.subject.keyword | drug-eluting stents | - |
dc.subject.keyword | dual antiplatelet therapy | - |
dc.subject.keyword | treatment outcome | - |
dc.contributor.alternativeName | Kim, Jung Sun | - |
dc.contributor.affiliatedAuthor | 김중선 | - |
dc.contributor.affiliatedAuthor | 남정모 | - |
dc.contributor.affiliatedAuthor | 이승준 | - |
dc.contributor.affiliatedAuthor | 최동훈 | - |
dc.contributor.affiliatedAuthor | 홍성진 | - |
dc.contributor.affiliatedAuthor | 홍명기 | - |
dc.contributor.affiliatedAuthor | 고영국 | - |
dc.contributor.affiliatedAuthor | 김병극 | - |
dc.contributor.affiliatedAuthor | 장양수 | - |
dc.contributor.affiliatedAuthor | 박은철 | - |
dc.citation.volume | 9 | - |
dc.citation.startPage | 954704 | - |
dc.identifier.bibliographicCitation | FRONTIERS IN CARDIOVASCULAR MEDICINE, Vol.9 : 954704, 2022-08 | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.